Profile data is unavailable for this security.
About the company
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.
- Revenue in USD (TTM)24.69bn
- Net income in USD123.00m
- LocationGilead Sciences Inc333 LAKESIDE DRFOSTER CITY 94404United StatesUSA
- Phone+1 (650) 574-3000
- Fax+1 (650) 578-9264
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|GILD:NSQ since |
|MYR GmbH||Announced||10 Dec 2020||10 Dec 2020Announced||0.95%||1.75bn|
|Immunomedics Inc||Deal completed||13 Sep 2020||13 Sep 2020Deal completed||-6.37%||20.77bn|
|Forty Seven Inc||Deal completed||02 Mar 2020||02 Mar 2020Deal completed||-11.48%||4.88bn|